Mothers who use methamphetamine during pregnancy can transfer the drug through the placenta to their babies, according to a report in the September issue of the Archives of Disease in Childhood. Fetal and Neonatal Edition.
Mothers who use methamphetamine during pregnancy can transfer the drug through the placenta to their babies, according to a report in the September issue of the Archives of Disease in Childhood. Fetal and Neonatal Edition.
Facundo Garcia-Bournissen, MD, of the University of Toronto in Ontario, Canada, and colleagues analyzed hair samples referred to their laboratory for drug testing from hospitals throughout Canada between 1997 and 2005. The survey included more than 34,000 tests representing more than 8,000 individuals.
The investigators found that 396 individuals and 11 mother-baby pairs tested positive for methamphetamine. Levels of the drug in mothers and neonates correlated significantly. Of the 171 individuals who tested positive for methamphetamine and who were also tested for other drugs of abuse, 83.5% tested positive for at least one other drug (65% for cocaine, 37.6% for marijuana and 30.2 % for opiates).
“Because neonatal hair grows in the last trimester of pregnancy, a positive hair test for methamphetamine in the baby is a biomarker of maternal addiction, as the mother has long known she is pregnant by the seventh month of pregnancy,” the authors write.
Garcia-Bournissen F, Rokach B, Karaskov T, et al. Methamphetamine detection in maternal and neonatal hair: implications for fetal safety. Arch Dis Child Fetal Neonatal Ed. 2007;92:F351-F355.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More